CLDX : Analysis & Opinions

  1. Celldex Cancer Drug Did Well in Early Trial (CLDX)

    November 15, 2016
    Positive pre-clinical data for its CDX-1140 cancer drug has buoyed the beleaguered company.
  2. Celldex 3Q Loss $30M, or 29 Cents a Share (CLDX)

    November 8, 2016
    Celldex reported a 3Q loss of 29 cents a share, above Wall Street estimates.
  3. Celldex Buys Cancer Drug Co. for $62M Stock (CLDX)

    November 2, 2016
    Celldex is buying cancer drug maker Kolltan for $62.5 million in stock.The deal includes $172.5 million in future payments.
  4. Celldex Therapeutics Remains a Guessing Game

    September 20, 2016
    While the company has a large pipeline of drugs under development, its short-term sustainability is questionable amid a significant ...